Alexander R. Cobitz - Concepedia

Author

Alexander R. Cobitz

Also Known As

A COBITZ, A Cobitz, A R Cobitz, A. Cobitz, A. R. Cobitz, A., Cobitz, Alexander Cobitz, Alexander R Cobitz, Alexander R. Cobitz, Cobitz, A.

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Harvard University Brigham and Women's Hospital Universidad Panamericana

About

Alexander R. Cobitz is an author at GlaxoSmithKline (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	280
2	Biochemistry	3	3	241
3	Health Sciences	1	1	27
4	Natural Sciences	1	1	25
5	Cell Biology	1	1	25

Alexander R. Cobitz

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes Christopher M. Ryan, Martin I. Freed, Julie A. Rood, Diabetes Care	2006	287
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis Ajay Singh, Kevin Carroll, John J.V. McMurray, New England Journal of Medicine	2021	211
Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia Louis Holdstock, Amy M. Meadowcroft, Rayma Maier, Journal of the American Society of Nephrology Hemodialysis StudyDialysis TherapyPharmacotherapyRedox BiologyOxidative Stress	2015	189
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia Tadao Akizawa, Masaomi Nangaku, Taeko Yonekawa, Clinical Journal of the American Society of Nephrology	2020	111
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis Amy M. Meadowcroft, Borut Čižman, Louis Holdstock, Clinical Kidney Journal	2018	103
Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus John P. Bilezikian, Robert G. Josse, Richard Eastell, The Journal of Clinical Endocrinology & Metabolism	2013	98
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Tadao Akizawa, Yoshiharu Tsubakihara, Masaomi Nangaku, American Journal of Nephrology	2016	96
A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na <i>ï</i> ve type 2 diabetes mellitus patients João Borges, John P. Bilezikian, Angela R. Jones-Leone, Diabetes Obesity and Metabolism	2011	88
Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes J Rosenstock, Julie A. Rood, Alexander R. Cobitz, Diabetes Obesity and Metabolism	2006	88
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease Louis Holdstock, Borut Čižman, Amy M. Meadowcroft, Clinical Kidney Journal	2018	73

Page 1